Vaccine adjuvants for immunotherapy of melanoma
US6716422B1 · kind B1 · utility
14Cited by
10References
43Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 8, 1998 |
| Grant date | Apr 6, 2004 |
| Priority date | — |
| Expiry date | Oct 8, 2018 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides methods of inducing the production of cytolytic T lymphocytes directed against malignancy or infectious agent by a mammal and treating such disease such that deleterious side effects are minimized and treatment of metastatic melanomas are surprisingly and dramatically improved.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.